Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis

Retrovirology

Volumn 12, Issue 1, 2015, Pages

  Campos, Noëlie ^a   Myburgh, Renier ^c   Garcel, Aude ^a   Vautrin, Audrey ^b   Lapasset, Laure ^b   Nadal, Erika Schläpfer ^c   Mahuteau Betzer, Florence ^d   Najman, Romain ^a   Fornarelli, Pauline ^a   Tantale, Katjana ^b   Basyuk, Eugénia ^b   Séveno, Martial ^g   Venables, Julian P ^b   Pau, Bernard ^e   Bertrand, Edouard ^b   Wainberg, Mark A ^f   Speck, Roberto F ^c   Scherrer, Didier ^a   Tazi, Jamal ^b  

^a ABIVAX   (France)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Centre de Recherche   (France)

^e UNIV MONTPELLIER   (France)

^f MCGILL UNIVERSITY   (Canada)

^g INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

AIDS; Cap Binding Complex; HIV cure; New antiviral drug; Rev protein; RNA biogenesis; Splicing

Indexed keywords

ABX 464; ANTIVIRUS AGENT; LAMIVUDINE; RALTEGRAVIR; REV PROTEIN; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CAP BINDING COMPLEX; CELLULAR PARAMETERS; CONTROLLED STUDY; CYTOPLASM; DRUG TARGETING; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONOTHERAPY; MOUSE; MOUSE MODEL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RNA SEQUENCE; RNA SPLICING; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; ADULT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; SCID MOUSE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ADULT; ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MICE, SCID; VIRAL LOAD; VIRUS REPLICATION;

EID: 84928822404     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-015-0159-3     Document Type: Article

References (63)

1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun T-W, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329:174-80.
2. Moir S, Chun T-W, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223-48.
3. Chun T-W, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012;26:1261-8.
4. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304-7.
5. Richman DD. Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS. 2011;6:1-3.
6. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol. 1993;67:6365-78.
7. Karn J, Stoltzfus CM. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med. 2012;2:a006916.
8. Tazi J, Bakkour N, Marchand V, Ayadi L, Aboufirassi A, Branlant C. Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action. FEBS J. 2010;277:867-76.
9. Suhasini M, Reddy TR. Cellular proteins and HIV-1 Rev function. Curr HIV Res. 2009;7:91-100.
10. Romani B, Engelbrecht S, Glashoff RH. Functions of Tat. the versatile protein of human immunodeficiency virus type 1. J Gen Virol. 2010;91:1-12.
11. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol. 1998;52:491-532.
12. Fischer U, Pollard VW, Lührmann R, Teufel M, Michael MW, Dreyfuss G, et al. Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle. Nucleic Acids Res. 1999;27:4128-34.
13. Bakkour N, Lin Y-L, Maire S, Ayadi L, Mahuteau-Betzer F, Nguyen CH, et al. Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathog. 2007;3:1530-9.
14. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc Natl Acad Sci U S A. 2005;102:8764-9.
15. Rivalle C, Wendling F, Tambourin P, Lhoste JM, Bisagni E, Chermann JC. Antitumor amino-substituted pyrido[3",4":4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications. J Med Chem. 1983;26:181-5.
16. Chermann JC, Gruest J, Montagnier L, Wendling F, Tambourin P, Perrin M, et al. [Cytotoxic and antitumor activity of a new series of heterocyclic compounds: dipyrido (4,3-b) (3,4-f) indoles]. CR Hebd Seances Acad Sci, Ser D. Sci Nat. 1977;285:945-8.
17. Vilarem MJ, Charcosset JY, Primaux F, Gras MP, Calvo F, Larsen CJ. Differential effects of ellipticine and aza-analogue derivatives on cell cycle progression and survival of BALB/c 3T3 cells released from serum starvation or thymidine double block. Cancer Res. 1985;45:3906-11.
18. Auclair C. Multimodal action of antitumor agents on DNA. the ellipticine series. Arch Biochem Biophys. 1987;259:1-14.
19. Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics. 2010;26:873-81.
20. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R, et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res. 2008;68:657-63.
21. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol. 2009;16:670-6.
22. Venables JP, Lapasset L, Gadea G, Fort P, Klinck R, Irimia M, et al. MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation. Nat Commun. 2013;4:2480.
23. Bai Y, Tambe A, Zhou K, Doudna JA. RNA-guided assembly of Rev-RRE nuclear export complexes. Elife. 2014;3, e03656.
24. Nawroth I, Mueller F, Basyuk E, Beerens N, Rahbek UL, Darzacq X, et al. Stable assembly of HIV-1 export complexes occurs cotranscriptionally. RNA. 2014;20:1-8.
25. Vercruysse T, Daelemans D. HIV-1 Rev multimerization: mechanism and insights. Curr HIV Res. 2013;11:623-34.
26. Müller-McNicoll M, Neugebauer KM. How cells get the message: dynamic assembly and function of mRNA-protein complexes. Nat Rev Genet. 2013;14:275-87.
27. Taniguchi I, Mabuchi N, Ohno M. HIV-1 Rev protein specifies the viral RNA export pathway by suppressing TAP/NXF1 recruitment. Nucleic Acids Res. 2014;42:6645-58.
28. Worch R, Niedzwiecka A, Stepinski J, Mazza C, Jankowska-Anyszka M, Darzynkiewicz E, et al. Specificity of recognition of mRNA 5' cap by human nuclear cap-binding complex. RNA. 2005;11:1355-63.
29. Mazza C, Ohno M, Segref A, Mattaj IW, Cusack S. Crystal structure of the human nuclear cap binding complex. Mol Cell. 2001;8:383-96.
30. Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol. 2012;19:72-84.
31. Mazza C, Segref A, Mattaj IW, Cusack S. Large-scale induced fit recognition of an m(7)GpppG cap analogue by the human nuclear cap-binding complex. EMBO J. 2002;21:5548-57.
32. Denton PW, García JV. Humanized mouse models of HIV infection. AIDS Rev. 2011;13:135-48.
33. Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology. 2011;8:65.
34. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA. Human immunodeficiency virus infection of human-PBL-SCID mice. Science. 1991;251:791-4.
35. Nischang M, Sutmuller R, Gers-Huber G, Audigé A, Li D, Rochat M-A, et al. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS ONE. 2012;7, e38853.
36. Baxter AE, Russell RA, Duncan CJA, Moore MD, Willberg CB, Pablos JL, et al. Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. Cell Host Microbe. 2014;16:711-21.
37. Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol. 2008;62:425-43.
38. Cullen BR. Nuclear mRNA export. insights from virology. Trends Biochem Sci. 2003;28:419-24.
39. Malim MH, Freimuth WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med. 1992;176:1197-201.
40. Nabel GJ, Fox BA, Post L, Thompson CB, Woffendin C. A molecular genetic intervention for AIDS-effects of a transdominant negative form of Rev. Hum Gene Ther. 1994;5:79-92.
41. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A. 1996;93:2889-94.
42. Heguy A. Inhibition of the HIV Rev transactivator: a new target for therapeutic intervention. Front Biosci. 1997;2:d283-97.
43. Nakaya T, Iwai S, Fujinaga K, Otsuka E, Ikuta K. Inhibition of HIV-1 replication by targeting the Rev protein. Leukemia. 1997;11 Suppl 3:134-7.
44. Nakaya T, Iwai S, Fujinaga K, Sato Y, Otsuka E, Ikuta K. Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein. Antimicrob Agents Chemother. 1997;41:319-25.
45. Zapp ML, Young DW, Kumar A, Singh R, Boykin DW, Wilson WD, et al. Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds. Bioorg Med Chem. 1997;5:1149-55.
46. Ratmeyer L, Zapp ML, Green MR, Vinayak R, Kumar A, Boykin DW, et al. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. Biochemistry. 1996;35:13689-96.
47. Shuck-Lee D, Chen FF, Willard R, Raman S, Ptak R, Hammarskjold M-L, et al. Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 2008;52:3169-79.
48. DeJong ES, Chang C-E, Gilson MK, Marino JP. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1. Biochemistry. 2003;42:8035-46.
49. Fasken MB, Saunders R, Rosenberg M, Brighty DW. A leptomycin B-sensitive homologue of human CRM1 promotes nuclear export of nuclear export sequence-containing proteins in Drosophila cells. J Biol Chem. 2000;275:1878-86.
50. Cheng H, Dufu K, Lee C-S, Hsu JL, Dias A, Reed R. Human mRNA export machinery recruited to the 5' end of mRNA. Cell. 2006;127:1389-400.
51. Strässer K, Masuda S, Mason P, Pfannstiel J, Oppizzi M, Rodriguez-Navarro S, et al. TREX is a conserved complex coupling transcription with messenger RNA export. Nature. 2002;417:304-8.
52. Masuda S, Das R, Cheng H, Hurt E, Dorman N, Reed R. Recruitment of the human TREX complex to mRNA during splicing. Genes Dev. 2005;19:1512-7.
53. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2:a007161.
54. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology. 2012;9:82.
55. Ay E, Banati F, Mezei M, Bakos A, Niller HH, Buzás K, et al. Epigenetics of HIV infection: promising research areas and implications for therapy. AIDS Rev. 2013;15:181-8.
56. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology. 2013;10:67.
57. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell. 2011;144:16-26.
58. Luco RF, Misteli T. More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Curr Opin Genet Dev. 2011;21:366-72.
59. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science. 2010;327:996-1000.
60. Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol. 2009;485:427-33.
61. Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother. 2003;47:747-54.
62. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis. 2009;200:1202-6.
63. McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorino PM, Francis DP, et al. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods. 1985;76:171-83.